Drugs that contain Zoledronic Acid
1. List of Reclast drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8052987 | NOVARTIS | Method of administering bisphosphonates |
Oct, 2023
(8 months from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(5 years from now) | |
|
US7932241
(Pediatric) | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(5 years from now) | |
Market Authorisation Date: 16 April, 2007
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis
Dosage: INJECTABLE;INTRAVENOUS
How can I launch a generic of RECLAST before it's patent expiration?
More Information on Dosage
2. List of Zometa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(2 years from now) | |
|
US8324189
(Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(2 years from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(5 years from now) | |
Market Authorisation Date: 20 August, 2001
Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy
Dosage: INJECTABLE;INTRAVENOUS
How can I launch a generic of ZOMETA before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic